Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?

被引：127

作者：

Freemantle, N ^{[1
]}

机构：

[1] Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England

来源：

BRITISH MEDICAL JOURNAL | 2001年 / 322卷 / 7292期

关键词：

D O I：

10.1136/bmj.322.7292.989

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：989 / 991

页数：3

共 16 条

[1] Subgroup analysis and other (mis)uses of baseline data in clinical trials
Assmann, SF
Pocock, SJ
Enos, LE
Kasten, LE
[J]. LANCET, 2000, 355 (9209) : 1064 - 1069
[2] The evidence for β blockers in heart failure -: Equals or surpasses that for angiotensin converting enzyme inhibitors
Cleland, JGF
McGowan, J
Clark, A
Freemantle, N
[J]. BRITISH MEDICAL JOURNAL, 1999, 318 (7187) : 824 - 825
[3] *DEP HHS FDA, 1998, FED REGISTER, V63, P49583
[4] Carvedilol and the food and drug administration (FDA) approval process: The FDA paradigm and reflections on hypothesis testing
Fisher, LD
[J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (01): : 16 - 39
[5] SOMETHING ROTTEN IN THE STATE OF CLINICAL AND ECONOMIC EVALUATIONS
FREEMANTLE, N
MAYNARD, A
[J]. HEALTH ECONOMICS, 1994, 3 (02) : 63 - 67
[6] Problems with the interpretation of pharmacoeconomic analyses - A review of submissions to the Australian pharmaceutical benefits scheme
Hill, SR
Mitchell, AS
Henry, DA
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (16): : 2116 - 2121
[7] Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure -: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
Hjalmarson, Å
Goldstein, S
Fagerberg, B
Wedel, H
Waagstein, F
Kjekshus, J
Wikstrand, J
El Allaf, D
Vítovec, J
Aldershvile, J
Halinen, M
Dietz, R
Neuhaus, KL
Jánosi, A
Thorgeirsson, G
Dunselman, PHJM
Gullestad, L
Kuch, J
Herlitz, J
Rickenbacher, P
Ball, S
Gottlieb, S
Deedwania, P
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (10): : 1295 - 1302
[8] End-point interpretation in clinical trials:: The case for discipline
Moyé, LA
[J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (01): : 40 - 49
[9] *NAT I CLIN EXC, 2001, INT GUID MAN SPONS
[10] A CONSUMERS GUIDE TO SUBGROUP ANALYSES
OXMAN, AD
GUYATT, GH
[J]. ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) : 78 - 84

← 1 2 →